Strahl Lab Research
The genetic blueprint of life occurs in the form of DNA, which is faithfully packaged within the nucleus of each cell in our body. DNA packaging, and its organization in the nucleus, is regulated by a class of proteins called histones. These proteins create individual histone-DNA complexes, referred to as nucleosomes, which are further folded into higher-order chromatin structures that are poorly defined (Figure at right).
It is therefore significant to ask:
(i) How do distinct chromosomal domains such as “euchromatin” and “heterochromatin” become established and maintained?
(ii) How is the underlying DNA within this highly compact and repressive chromatin environment made accessible to the protein complexes that utilize it?
Brian Strahl's lab is addressing these questions by taking advantage of multiple model organisms and through applying a combination of genetic, biochemical and high-throughput proteomic approaches.
One mechanism that has emerged as a major regulator of the organization and function of chromatin are histone post-translational modifications (PTMs). Surprisingly, a vast number of covalent modifications, such as acetylation, methylation, ubiquitylation and phosphorylation exist on histones.
Numerous studies indicate that these modifications work together in the form of a ‘histone code’ to regulate chromatin-based activities. This code functions, in part, through the direct recruitment of protein modifiers to the sites of modification, which then alter the organizational state of chromatin and/or facilitate a biological process (e.g., transcription).
A famous example is the recruitment of HP1 (heterochromatin protein 1) to histone H3 that is methylated at lysine 9, resulting in the formation of highly compact, transcriptionally inert heterochromatin in cells (Figure above).
Histone modifications in RNA polymerase II transcription
Of the known histone modifications, histone methylation and ubiquitylation have recently received much attention and are only now becoming understood. Recent insights indicate that these modifications play a fundamental role in the organization of chromatin and in the activation and repression of genes controlled by RNA polymerase II.
The Strahl lab and others have found, for example, that a variety of enzymes which either methylate (e.g., Set1 and Set2) or ubiquitylate (e.g., Rad6) histones, associate with RNA polymerase II during the elongation cycle of transcription. While Set2 associates directly with the C-terminal domain of RNA polymerase II, Rad6 and Set1 associate with the polymerase through an interaction with the PAF transcription elongation complex (Figure below).
This finding indicates that histone modifications play a fundamental role in the transcription process. We seek to understand how these enzymes and their modifications regulate chromatin-based transcription and how defects in these processes result in diseases such as cancer.
One major focus of our lab is the histone methyltransferase Set2. We have shown that this enzyme “travels” with RNA polymerase II during gene transcription to mediate histone H3 lysine 36 methylation (Figure above).
The function of this enzyme remained elusive until recent work showed that the methylation by Set2 recruits a histone deacetylase complex (Rpd3S) to the bodies of genes. As it turns out, RNA polymerase II transcription involves the recruitment of histone acetyltransferases that function to help disrupt nucleosomes in front of the polymerase.
Set2’s function therefore is to recruit a histone deacetylase enzyme that restores the acetylation levels to their previous state after the passage of the polymerase. Without this mechanism, acetylation levels remain high in the coding region and cryptic transcription start sites are inappropriately used.
To study histone modifictaions in gene regulation, our lab is using budding yeast (Saccharomyces cerevisiae) as a model organism. This organism provides a fantastic opportunity to employ both biochemistry and genetics to solve complex problems.
For example, we can easily mutate the histones and chromatin-modifying enzymes we study and examine how their mutation affects chromatin organization, transcription and other biological processes. We can also insert affinity purification tags on any protein at will to study who they are associated with and where they occur in the genome (and if they get recruited to various ‘marks’). Thus, this powerful organism affords a unique opportunity to study the fundamentals of chromatin modifications.
Significantly, most, if not all, of the enzymes and modifications we study in yeast are conserved in humans. Thus, what we learn in yeast is directly applicable to how these enzymes operate in human cells, which is relevant as many of these enzymes have been associated with various human diseases including cancer.
High-thoughput proteomics and studies into the ‘histone code’
More recently, our lab has been engaged in a large-scale, high-throughput proteomics project to uncover the function of histone modifications using peptide arrays. My interest in this stems from the fact that as a postdoc in David Allis’ lab, we proposed the ‘histone code’ hypothesis to explain how distinct covalent histone PTMs might work together to regulate epigenetic inheritance, gene expression and the control of cell growth, differentiation and disease.
However, progress in this area has been slow due to the lack of new tools to study it. Because of this, we set out to develop a novel ‘histone code’ peptide array platform to explore this critical question in chromatin biology (Figure at right).
Since initiating this project, we have shown how a number of effector proteins are influenced by combinatorial histone PTMs. We are also collaborating with a wide number of labs across the world to decipher the binding potential of newly identified histone "reading" proteins.
Using epigenetics to fight breast cancer
The Strahl lab has also shifted into the understanding and treatment of breast cancer, as it is becoming increasingly clear that epigenetics plays a central role in breast cancer development.
In collaboration with Dr. Pilar Blancafort’s lab at The Univeristy of Western Australia, we have focused on the design and implementation of novel artificial transcription factors that are capable of specifically targeting epigenetic modifications (i.e., DNA methylation) to breast cancer stem cell genes that are important for breast cancer proliferation.
We document in two newly published papers in 2012 the use of these transcription factors to shut down breast cancer proliferation in cell culture and in mouse models.
Keywords: histones, histone post-translational modifications, epigenetics, gene regulation, Brian D. Strahl, UNC Chapel Hill